Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis

Article Clinical Neurology

Rebound activity after fingolimod cessation: A case - control study

Andres Barboza et al.

Summary: This study aimed to identify risk factors for developing RA after fingolimod cessation and describe the characteristics, management, and evolution of RA. The results showed that no risk factors could be identified in this case-control study.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry

Niklas Frahm et al.

Summary: This study analyzed treatment switches and changes over time in sociodemographic/clinical characteristics of people with multiple sclerosis (MS) receiving fingolimod therapy. The study found that the duration of fingolimod treatment has decreased over time, and female and young patients have a shorter time on fingolimod therapy.

NEUROLOGY AND THERAPY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Multiple Sclerosis Relapses Following Cessation of Fingolimod

Charles B. Malpas et al.

Summary: Disease reactivation following fingolimod cessation is more common in younger patients, those with greater disease activity prior to cessation, and in those who switch to low-efficacy therapy.

CLINICAL DRUG INVESTIGATION (2022)

Add to Collection

Article Clinical Neurology

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series

Silvia Delgado et al.

Summary: In this study, the authors presented six patients with relapsing-remitting MS who experienced an unexpected increase in disease activity after transitioning from fingolimod to DMF. Despite being stable on fingolimod for at least 1 year, all patients experienced relapse with enhancing lesions after switching to DMF. Additional studies are needed to determine the most effective treatment strategy after discontinuing fingolimod.

BMC NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab

Steffen Pfeuffer et al.

Summary: In a retrospective evaluation of a prospective dual-centre alemtuzumab cohort of 170 patients, it was found that patients previously treated with fingolimod had suboptimal disease control and increased risk of secondary autoimmunity following alemtuzumab treatment. These findings can guide the improvement of MS therapeutic management.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study

Marine Boudot de la Motte et al.

Summary: This study investigated the frequency and risk factors of relapses during the wash-out period (WP) between cessation of last DMT and initiation of anti-CD20 mAb in RR-MS patients. Results indicated that previous treatment with Fingolimod (Fg) and longer WP duration were identified as risk factors for relapses. The study suggests shortening the WP duration, especially after Fg treatment, to prevent relapses.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology